Herbalife International, Inc.

Herbalife International, Inc.

Herbalife International, Inc.

Overview
Date Founded

1980

Headquarters

1800 Century Park East,Century City, CA 90067

Type of Company

Private

Industries

Wholesale: Consumer Non-Durables/Sundries
Retail: Food & Beverage

Company Description

Herbalife International, Inc. manufactures and distributes personal health care products such as weight control mixes, nutritional supplements, shampoos, lotions, sunscreens, and body oils. It also provides weight management products to support weight loss and a healthy lifestyle. The company was founded in 1980 by Mark Hughes and is headquartered in Century City, CA.

Executives & Employees

Chairman & Chief Executive Officer

Chief Financial Officer

General Counsel

Senior Director

Plant Controller

Sales & Marketing Coordinator

Production Coordinator

Coordinator

Sales Coordinator

Marketing Director

Subscribe now to see full list of current and former executives
Board of Directors

Executive Chairman at Herbalife Ltd.

Subscribe now to see full list of current and former board members
Paths to Herbalife International, Inc.
Potential Connections via
Relationship Science
You
Herbalife International, Inc.
Recent Transactions
Details Hidden

J. H. Whitney & Co. LLC, Golden Gate Private Equity, Inc. purchase Herbalife International, Inc.

Subscribe now to see full list of recent transations
Transaction Advisors
Investment Advisor

Advised onJ. H. Whitney & Co. LLC, Golden Gate Private Equity, Inc. purchase Herbalife International, Inc.

Accountant

Advised onJ. H. Whitney & Co. LLC, Golden Gate Private Equity, Inc. purchase Herbalife International, Inc.

Legal Advisor

Advised onJ. H. Whitney & Co. LLC, Golden Gate Private Equity, Inc. purchase Herbalife International, Inc.

Subscribe now to see 2+ more transaction advisors
Subscribe now to see transaction advisors for over 2.5 million organizations
Advisors & Consultants
Subscribe now to see advisors & consultants for over 2.5 million organizations
Legal Advisor

Former Partner at Bingham McCutchen LLP

Legal Advisor

Vice President at The Glover Park Group, Inc.

Subscribe now to see advisors & consultants for over 2.5 million organizations
Political Donations
$1,000
2014
$1,000
2014
$2,000
2013
Subscribe now to see 5 more political donations
Political Donations Received
$1,000
2014
$1,000
2014
$2,000
2013
Subscribe now to see 5 more political donations received
Suppliers
Biocon Ltd. Medical Support Services | Bangalore, KA

Biocon, India's largest biotech company is focused on delivering affordable innovation. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe. Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon. Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets. Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 75 countries. As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market. Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene. Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle. With the successful commercial launch of its first anti-cancer drug and several promising discovery partnerships in the clinic, the Company remains committed to scaling new heights in frontier science and achieving new milestones in affordable medicine

Subscribe now to see suppliers for over 2.5 million organizations